Boston Scientific (NYSE: BSX) Q2 2026 sales hit $5.44B with EPS beat
Rhea-AI Filing Summary
Boston Scientific Corporation reported strong results for the quarter ended June 30, 2026, with net sales of $5.442 billion, up 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis versus a year earlier. GAAP net income attributable to common stockholders was $907 million, or $0.61 per diluted share, compared with $797 million, or $0.53 per share. Adjusted EPS was $0.86, up from $0.75 and above the company’s guidance range of $0.82 to $0.84.
MedSurg net sales were $1.818 billion, up 5.9 percent reported, while Cardiovascular reached $3.624 billion, up 8.3 percent. Regional growth was 6.2 percent in the U.S., 11.2 percent in Asia-Pacific and 22.4 percent in Latin America and Canada on a reported basis.
The company completed a $2 billion accelerated share repurchase program, buying approximately 40 million shares, and invested $1.5 billion for an approximately 34 percent stake in MiRus LLC with an exclusive option on its TAVR business. For 2026, it projects reported net sales growth of 5.5 to 6.5 percent and adjusted EPS of $3.28 to $3.32, with third-quarter adjusted EPS expected at $0.80 to $0.82.
Positive
- Q2 2026 adjusted EPS was $0.86, up from $0.75 a year earlier and above the company’s guidance range of $0.82–$0.84.
- Net sales grew 7.5% year over year to $5.442 billion, at the high end of the company’s reported growth guidance range of 5.5%–7.5%.
Negative
- None.
Filing Explained
TruSelect has FDA clearance, while three named devices remain investigational and FARAFLEX has only begun pivotal-trial enrollment.
This Form 8-K reports the
The filing says the TruSelect 2.6 Microcatheter received FDA 510(k) clearance, while SIEGEL, SEISMIQ 4CE, and FARAFLEX are investigational and not available for sale under U.S. law.
It also reports that enrollment commenced in the pivotal trial for FARAFLEX, placing that device in a clinical-testing stage rather than a disclosed commercial-launch stage.
A later filing would need to update the named investigational devices' regulatory status or report the FARAFLEX pivotal-trial outcome.
8-K Event Classification
3 items: 0.00, 2.02, 9.01
3 items
Item 0.00
Item 0.00
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 net sales: $5.442 billion
Q2 2026 GAAP net income attributable to common stockholders: $907 million
Q2 2026 GAAP diluted EPS: $0.61
+5 more
8 metrics
Q2 2026 net sales
$5.442 billion
Quarter ended June 30, 2026; 7.5% reported growth vs prior-year period
Q2 2026 GAAP net income attributable to common stockholders
$907 million
Quarter ended June 30, 2026; up from $797 million in Q2 2025
Q2 2026 GAAP diluted EPS
$0.61
Quarter ended June 30, 2026; up from $0.53 a year earlier
Q2 2026 adjusted EPS
$0.86
Quarter ended June 30, 2026; up from $0.75 and above guidance of $0.82–$0.84
Completed ASR size
$2 billion
Accelerated share repurchase program repurchasing approximately 40 million shares
MiRus LLC investment
$1.5 billion
Investment for approximately 34% equity stake and exclusive option to acquire MiRus TAVR business
Full-year 2026 adjusted EPS guidance
$3.28–$3.32
Company’s estimated adjusted EPS range for full year 2026
Full-year 2026 reported net sales growth guidance
5.5%–6.5%
Expected reported net sales growth versus prior-year period
Key Terms
operational net sales growth, organic net sales growth, accelerated share repurchase program, Investigational Device Exemption trial, +1 more
5 terms
operational net sales growth financial
"growing 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis"
Operational net sales growth measures how a company's sales changed from one period to the next after removing effects that mask underlying performance, such as currency swings, acquisitions, or one-time accounting shifts. Investors care because it shows the true momentum in demand and business operations—like judging how much a garden produced without counting new planting beds or temporary weather boosts—so you can compare performance across time and companies more fairly.
organic net sales growth financial
"7.0 percent on an operational1 and organic2 basis, all compared to the prior year period"
Organic net sales growth measures how much a company’s core revenue rose from its existing operations, excluding effects from buying or selling businesses and from changes in currency values. Investors use it to see whether customers are actually buying more or paying higher prices — like checking growth from the same orchard year-to-year rather than counting fruit from newly added orchards — which helps assess true demand and underlying business health.
Investigational Device Exemption trial medical
"findings at EuroPCR from the FRACTURE Investigational Device Exemption trial, which met its primary endpoints"
510(k) clearance regulatory
"Received U.S. Food and Drug Administration 510(k) clearance for the TruSelect 2.6 Microcatheter"
A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.
Earnings Snapshot
Net sales Q2 2026: $5.442 billion · Guidance included
Quarter and six months ended June 30, 2026
Net sales Q2 2026
$5.442 billion
7.5% reported growth versus $5.061 billion in Q2 2025
GAAP diluted EPS Q2 2026
$0.61
up from $0.53 in Q2 2025
Adjusted EPS Q2 2026
$0.86
up from $0.75 in Q2 2025 and above guidance of $0.82–$0.84
Net income attributable to BSX Q2 2026
$907 million
up from $797 million a year earlier
Guidance
For full-year 2026, the company expects reported net sales growth of 5.5% to 6.5%, organic growth of 5% to 6%, and adjusted EPS of $3.28 to $3.32. For Q3 2026, it guides to reported and organic net sales growth of 3% to 5% and adjusted EPS of $0.80 to $0.82.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Boston Scientific (BSX) perform financially in Q2 2026?
Boston Scientific reported Q2 2026 net sales of $5.442 billion, up 7.5% year over year. GAAP diluted EPS was $0.61 versus $0.53 a year earlier, and adjusted EPS was $0.86, up from $0.75 and above guidance of $0.82–$0.84.
What segment and regional growth did Boston Scientific (BSX) report for Q2 2026?
In Q2 2026, MedSurg net sales were $1.818 billion, up 5.9% reported, and Cardiovascular sales were $3.624 billion, up 8.3%. Regionally, reported growth was 6.2% in the U.S., 6.1% in EMEA, 11.2% in APAC, and 22.4% in Latin America and Canada.
What is Boston Scientific’s (BSX) earnings guidance for full-year 2026?
For full-year 2026, Boston Scientific estimates reported net sales growth of 5.5% to 6.5% and organic growth of 5% to 6%. It projects adjusted EPS of $3.28 to $3.32, excluding specified charges and credits such as amortization, restructuring and litigation-related items.
What outlook did Boston Scientific (BSX) give for Q3 2026?
For Q3 2026, Boston Scientific expects reported and organic net sales growth of 3% to 5%. The company projects adjusted EPS between $0.80 and $0.82, excluding certain charges and credits, with organic growth defined to exclude foreign currency and specific acquisition/divestiture impacts.
What capital allocation actions did Boston Scientific (BSX) highlight with Q2 2026 results?
Boston Scientific completed a $2 billion accelerated share repurchase program, buying about 40 million shares. It also invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire the company’s TAVR business.
What major clinical and regulatory updates did Boston Scientific (BSX) report?
The company highlighted positive data from the FRACTURE IDE trial and AVANT GUARD and ELEVATE-PF studies for FARAPULSE and FARAFLEX systems. It also received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter, expanding its embolization device portfolio.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_____________________________________________________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________
Date of Report (Date of earliest event reported): July 29, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of Principal Executive Offices) (Zip Code)
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On July 29, 2026, Boston Scientific Corporation issued a press release announcing financial results for the second quarter ended June 30, 2026. A copy of the release is furnished with this report as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit No. Description
99.1 Press Release issued by Boston Scientific Corporation dated July 29, 2026
104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL
document
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | July 29, 2026 | BOSTON SCIENTIFIC CORPORATION | |||||||||
| By: | /s/ Susan Thompson | ||||||||||
| Susan Thompson | |||||||||||
| Vice President, Chief Corporate Counsel and Assistant Secretary | |||||||||||
FOR IMMEDIATE RELEASE
Boston Scientific announces results for second quarter 2026
Marlborough, Mass. (July 29, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted3 EPS of $0.86 for the period, compared to $0.75 a year ago.
"Our team delivered a solid quarter while continuing to navigate a dynamic environment," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."
Second quarter financial results and recent developments:
•Reported net sales of $5.442 billion, representing an increase of 7.5 percent on a reported basis, compared to the company's guidance range of 5.5 to 7.5 percent; and 7.0 percent on an operational and organic basis, compared to the company's guidance range of 5 to 7 percent, all compared to the prior year period.
•Reported GAAP net income attributable to Boston Scientific common stockholders of $0.61 per share, and achieved adjusted EPS of $0.86 per share, compared to the guidance range of $0.82 to $0.84 per share.
•Achieved the following net sales growth in each reportable segment, compared to the prior year period:
◦MedSurg: 5.9 percent reported, 5.4 percent operational and organic
◦Cardiovascular: 8.3 percent reported, 7.8 percent operational and organic
•Achieved the following net sales growth in each region, compared to the prior year period:
◦United States (U.S.): 6.2 percent reported and operational
◦Europe, Middle East and Africa (EMEA): 6.1 percent reported and 4.2 percent operational
◦Asia-Pacific (APAC): 11.2 percent reported and operational
◦Latin America and Canada (LACA): 22.4 percent reported and 16.2 percent operational
•Completed the previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.
•Invested $1.5 billion in MiRus LLC, which is developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system, in return for an approximately 34% equity stake and exclusive option to acquire the MiRus TAVR business.4
•Presented late-breaking findings at EuroPCR from the FRACTURE Investigational Device Exemption trial, which met its primary endpoints with the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter, demonstrating high rates of freedom from major adverse cardiac events at 30 days as well as procedural success in patients with severely calcified coronary artery disease.4
•Announced clinical trial results that were presented in late-breaking sessions at Heart Rhythm 2026 including:
◦The AVANT GUARD study of FARAPULSE™ Pulsed Field Ablation (PFA) for the treatment of persistent atrial fibrillation (AF) in patients who had not previously been treated for their condition. Data met all safety and effectiveness endpoints and demonstrated statistical superiority of FARAPULSE PFA over anti-arrhythmic drugs with significantly higher primary effectiveness.
◦The ELEVATE-PF feasibility study of the FARAFLEX™ Mapping and PFA Catheter — a novel large focal, high-density map-and-ablate catheter — in patients with paroxysmal and persistent AF. The trial demonstrated strong lesion durability validated by cardiac remapping, with no reported cases of pulmonary vein stenosis, hemolysis, coronary spasm or clinical stroke.4
•Commenced enrollment in the pivotal FARADIGM clinical trial to evaluate the safety and effectiveness of the FARAFLEX Mapping and PFA Catheter for treating patients with paroxysmal and persistent AF.4
•Received U.S. Food and Drug Administration 510(k) clearance for the TruSelect™ 2.6 Microcatheter, expanding Boston Scientific's embolization portfolio with a device designed to provide physicians with a single solution for navigation and efficient embolic delivery during minimally invasive procedures.
1. Operational net sales growth excludes the impact of foreign currency fluctuations.
2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.
3. Adjusted EPS excludes the impact of certain charges (credits) as defined below within the "Use of Non-GAAP Financial Measures" section.
4. The SIEGEL Balloon Expandable TAVR system, the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter and the FARAFLEX Mapping and PFA Catheter are investigational devices. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
Net sales for the second quarter by business and region:
| Increase/(Decrease) | |||||||||||||||||||||||||||||||||||||||||
| Three Months Ended June 30, | Reported Basis | Impact of Foreign Currency Fluctuations | Operational Basis | Impact of Certain Acquisitions/Divestitures | Organic Basis | ||||||||||||||||||||||||||||||||||||
| (in millions) | 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||
| Endoscopy | $ | 793 | $ | 737 | 7.6 | % | (0.7) | % | 7.0 | % | — | % | 7.0 | % | |||||||||||||||||||||||||||
| Urology | 684 | 676 | 1.1 | % | (0.3) | % | 0.8 | % | — | % | 0.8 | % | |||||||||||||||||||||||||||||
| Neuromodulation | 341 | 303 | 12.7 | % | (0.6) | % | 12.2 | % | — | % | 12.2 | % | |||||||||||||||||||||||||||||
| MedSurg | 1,818 | 1,716 | 5.9 | % | (0.5) | % | 5.4 | % | — | % | 5.4 | % | |||||||||||||||||||||||||||||
| Cardiovascular | 3,624 | 3,345 | 8.3 | % | (0.6) | % | 7.8 | % | — | % | 7.8 | % | |||||||||||||||||||||||||||||
| Net Sales | $ | 5,442 | $ | 5,061 | 7.5 | % | (0.5) | % | 7.0 | % | — | % | 7.0 | % | |||||||||||||||||||||||||||
| Increase/(Decrease) | |||||||||||||||||||||||||||||||||||||||||
| Three Months Ended June 30, | Reported Basis | Impact of Foreign Currency Fluctuations | Operational Basis | ||||||||||||||||||||||||||||||||||||||
| (in millions) | 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||
| U.S. | $ | 3,426 | $ | 3,224 | 6.2 | % | — | % | 6.2 | % | |||||||||||||||||||||||||||||||
| EMEA | 932 | 878 | 6.1 | % | (1.9) | % | 4.2 | % | |||||||||||||||||||||||||||||||||
| APAC | 878 | 790 | 11.2 | % | (0.0) | % | 11.2 | % | |||||||||||||||||||||||||||||||||
| LACA | 206 | 169 | 22.4 | % | (6.2) | % | 16.2 | % | |||||||||||||||||||||||||||||||||
| Net Sales | $ | 5,442 | $ | 5,061 | 7.5 | % | (0.5) | % | 7.0 | % | |||||||||||||||||||||||||||||||
| Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely. | |||||||||||||||||||||||||||||||||||||||||
| Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not prepared in accordance with U.S. GAAP. | |||||||||||||||||||||||||||||||||||||||||
Guidance for Full Year and Third Quarter 2026
The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates adjusted EPS, excluding certain charges (credits), of $3.28 to $3.32.
The company estimates net sales growth for the third quarter of 2026, versus the prior year period, to be approximately 3 to 5 percent on a reported and organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $0.80 to $0.82.
The company has not provided reconciliations of the forward-looking adjusted EPS guidance to GAAP guidance as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges. The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.
Conference Call Information
Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the third quarter and full year 2026; our financial performance; acquisitions; clinical trials; our business plans and product
performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.
Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.
Use of Non-GAAP Financial Information
A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.
| CONTACT: | ||||||||||||||
| Media: | Chanel Hastings | Investors: | Lauren Tengler | |||||||||||
| 508-382-0288 (office) | 508-683-4479 (office) | |||||||||||||
| Media Relations | Investor Relations | |||||||||||||
| Boston Scientific Corporation | Boston Scientific Corporation | |||||||||||||
| chanel.hastings@bsci.com | BSXInvestorRelations@bsci.com | |||||||||||||
BOSTON SCIENTIFIC CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
| (in millions, except per share data) | 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net sales | $ | 5,442 | $ | 5,061 | $ | 10,646 | $ | 9,724 | |||||||||
| Cost of products sold (excluding amortization expense) | 1,594 | 1,637 | 3,184 | 3,090 | |||||||||||||
| Gross profit | 3,848 | 3,424 | 7,462 | 6,633 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Selling, general and administrative expenses | 1,803 | 1,716 | 3,583 | 3,312 | |||||||||||||
| Research and development expenses | 554 | 526 | 1,069 | 969 | |||||||||||||
| Royalty expense | 12 | 14 | 24 | 28 | |||||||||||||
| Amortization expense | 233 | 225 | 466 | 444 | |||||||||||||
| Intangible asset impairment charges | — | 46 | — | 46 | |||||||||||||
| Contingent consideration net expense (benefit) | (16) | (5) | (46) | 0 | |||||||||||||
| Restructuring net charges (credits) | 8 | 83 | 11 | 93 | |||||||||||||
| Litigation-related net charges (credits) | 76 | — | 76 | — | |||||||||||||
| 2,670 | 2,605 | 5,183 | 4,894 | ||||||||||||||
| Operating income (loss) | 1,178 | 819 | 2,279 | 1,740 | |||||||||||||
| Other income (expense): | |||||||||||||||||
| Interest expense | (96) | (90) | (186) | (172) | |||||||||||||
| Other, net | (23) | 213 | 129 | 179 | |||||||||||||
| Income (loss) before income taxes | 1,060 | 941 | 2,222 | 1,746 | |||||||||||||
| Income tax expense (benefit) | 155 | 146 | (21) | 279 | |||||||||||||
| Net income (loss) | 905 | 795 | 2,243 | 1,467 | |||||||||||||
| Net income (loss) attributable to noncontrolling interests | (2) | (2) | (4) | (4) | |||||||||||||
| Net income (loss) attributable to Boston Scientific common stockholders | $ | 907 | $ | 797 | $ | 2,247 | $ | 1,471 | |||||||||
| Net income (loss) per common share - basic | $ | 0.62 | $ | 0.54 | $ | 1.52 | $ | 0.99 | |||||||||
| Net income (loss) per common share - diluted | $ | 0.61 | $ | 0.53 | $ | 1.51 | $ | 0.98 | |||||||||
| Weighted-average shares outstanding | |||||||||||||||||
| Basic | 1,470.2 | 1,479.9 | 1,477.6 | 1,478.5 | |||||||||||||
| Diluted | 1,474.8 | 1,493.5 | 1,484.9 | 1,493.3 | |||||||||||||
| Amounts may not add due to rounding. | |||||||||||||||||
BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS
(Unaudited)
| Three Months Ended June 30, 2026 | |||||||||||||||||||||||||||||
| (in millions, except per share data) | Gross Profit | Operating Expenses | Operating Income (Loss) | Other Income (Expense) | Income (Loss) Before Income Taxes | Net Income (Loss) | Net Income (Loss) Attributable to Noncontrolling Interests | Net Income (Loss) Attributable to Boston Scientific Common Stockholders | Impact per Share | ||||||||||||||||||||
| Reported | $ | 3,848 | $ | 2,670 | $ | 1,178 | $ | (118) | $ | 1,060 | $ | 905 | $ | (2) | $ | 907 | $ | 0.61 | |||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||
| Amortization expense | — | (233) | 233 | — | 233 | 206 | 2 | 203 | 0.14 | ||||||||||||||||||||
| Acquisition/divestiture-related net charges/credits | 30 | (61) | 91 | 1 | 92 | 72 | — | 72 | 0.05 | ||||||||||||||||||||
| Restructuring and restructuring-related net charges/credits | 25 | (16) | 42 | — | 42 | 37 | — | 37 | 0.02 | ||||||||||||||||||||
| Litigation-related net charges/credits | — | (76) | 76 | — | 76 | 60 | — | 60 | 0.04 | ||||||||||||||||||||
| Investment portfolio net losses/gains and impairments | — | — | — | (2) | (2) | (2) | — | (2) | (0.00) | ||||||||||||||||||||
| EU MDR implementation costs | 4 | (3) | 7 | — | 7 | 6 | — | 6 | 0.00 | ||||||||||||||||||||
| IEEPA tariff refund | (83) | — | (83) | — | (83) | (77) | — | (77) | (0.05) | ||||||||||||||||||||
| Deferred tax expenses/benefits | — | — | — | — | — | 70 | — | 70 | 0.05 | ||||||||||||||||||||
| Adjusted | $ | 3,824 | $ | 2,281 | $ | 1,543 | $ | (120) | $ | 1,423 | $ | 1,275 | $ | 1 | $ | 1,275 | $ | 0.86 | |||||||||||
| Three Months Ended June 30, 2025 | |||||||||||||||||||||||||||||
| (in millions, except per share data) | Gross Profit | Operating Expenses | Operating Income (Loss) | Other Income (Expense) | Income (Loss) Before Income Taxes | Net Income (Loss) | Net Income (Loss) Attributable to Noncontrolling Interests | Net Income (Loss) Attributable to Boston Scientific Common Stockholders | Impact per Share | ||||||||||||||||||||
| Reported | $ | 3,424 | $ | 2,605 | $ | 819 | $ | 122 | $ | 941 | $ | 795 | $ | (2) | $ | 797 | $ | 0.53 | |||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||
| Amortization expense | — | (225) | 225 | — | 225 | 193 | 2 | 191 | 0.13 | ||||||||||||||||||||
| Goodwill and other intangible asset impairment charges | — | (46) | 46 | — | 46 | 37 | — | 37 | 0.02 | ||||||||||||||||||||
| Acquisition/divestiture-related net charges/credits | 46 | (92) | 138 | (230) | (92) | (92) | — | (92) | (0.06) | ||||||||||||||||||||
| Restructuring and restructuring-related net charges/credits | 37 | (124) | 161 | — | 161 | 142 | — | 142 | 0.10 | ||||||||||||||||||||
| Investment portfolio net losses/gains and impairments | — | — | — | (2) | (2) | (2) | — | (2) | (0.00) | ||||||||||||||||||||
| EU MDR implementation costs | 7 | (3) | 10 | — | 10 | 9 | — | 9 | 0.01 | ||||||||||||||||||||
| Deferred tax expenses/benefits | — | — | — | — | — | 45 | — | 45 | 0.03 | ||||||||||||||||||||
| Discrete tax items | — | — | — | — | — | 0 | — | 0 | 0.00 | ||||||||||||||||||||
| Adjusted | $ | 3,514 | $ | 2,114 | $ | 1,399 | $ | (110) | $ | 1,289 | $ | 1,127 | $ | 0 | $ | 1,127 | $ | 0.75 | |||||||||||
| An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document. | |||||||||||||||||||||||||||||
| Amounts may not add due to rounding. | |||||||||||||||||||||||||||||
BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS
(Unaudited)
| Six Months Ended June 30, 2026 | |||||||||||||||||||||||||||||
| (in millions, except per share data) | Gross Profit | Operating Expenses | Operating Income (Loss) | Other Income (Expense) | Income (Loss) Before Income Taxes | Net Income (Loss) | Net Income (Loss) Attributable to Noncontrolling Interests | Net Income (Loss) Attributable to Boston Scientific Common Stockholders | Impact per Share | ||||||||||||||||||||
| Reported | $ | 7,462 | $ | 5,183 | $ | 2,279 | $ | (57) | $ | 2,222 | $ | 2,243 | $ | (4) | $ | 2,247 | $ | 1.51 | |||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||
| Amortization expense | — | (466) | 466 | — | 466 | 410 | 5 | 406 | 0.27 | ||||||||||||||||||||
| Acquisition/divestiture-related net charges/credits | 57 | (118) | 175 | (36) | 139 | 103 | — | 103 | 0.07 | ||||||||||||||||||||
| Restructuring and restructuring-related net charges/credits | 47 | (29) | 77 | — | 77 | 69 | — | 69 | 0.05 | ||||||||||||||||||||
| Litigation-related net charges/credits | — | (76) | 76 | — | 76 | 60 | — | 60 | 0.04 | ||||||||||||||||||||
| Investment portfolio net losses/gains and impairments | — | — | — | (139) | (139) | (106) | — | (106) | (0.07) | ||||||||||||||||||||
| EU MDR implementation costs | 9 | (5) | 14 | — | 14 | 12 | — | 12 | 0.01 | ||||||||||||||||||||
| IEEPA tariff refund | (83) | — | (83) | — | (83) | (77) | — | (77) | (0.05) | ||||||||||||||||||||
| Deferred tax expenses/benefits | — | — | — | — | — | (250) | — | (250) | (0.17) | ||||||||||||||||||||
| Adjusted | $ | 7,492 | $ | 4,490 | $ | 3,002 | $ | (232) | $ | 2,771 | $ | 2,465 | $ | 1 | $ | 2,464 | $ | 1.66 | |||||||||||
| Six Months Ended June 30, 2025 | |||||||||||||||||||||||||||||
| (in millions, except per share data) | Gross Profit | Operating Expenses | Operating Income (Loss) | Other Income (Expense) | Income (Loss) Before Income Taxes | Net Income (Loss) | Net Income (Loss) Attributable to Noncontrolling Interests | Net Income (Loss) Attributable to Boston Scientific Common Stockholders | Impact per Share | ||||||||||||||||||||
| Reported | $ | 6,633 | $ | 4,894 | $ | 1,740 | $ | 6 | $ | 1,746 | $ | 1,467 | $ | (4) | $ | 1,471 | $ | 0.98 | |||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||
| Amortization expense | — | (444) | 444 | — | 444 | 383 | 4 | 378 | 0.25 | ||||||||||||||||||||
| Goodwill and other intangible asset impairment charges | — | (46) | 46 | — | 46 | 37 | — | 37 | 0.02 | ||||||||||||||||||||
| Acquisition/divestiture-related net charges/credits | 136 | (150) | 286 | (229) | 57 | 61 | — | 61 | 0.04 | ||||||||||||||||||||
| Restructuring and restructuring-related net charges/credits | 61 | (149) | 210 | — | 210 | 184 | — | 184 | 0.12 | ||||||||||||||||||||
| Investment portfolio net losses/gains and impairments | — | — | — | 6 | 6 | 5 | — | 5 | 0.00 | ||||||||||||||||||||
| EU MDR implementation costs | 15 | (7) | 23 | — | 23 | 19 | — | 19 | 0.01 | ||||||||||||||||||||
| Deferred tax expenses/benefits | — | — | — | — | — | 91 | — | 91 | 0.06 | ||||||||||||||||||||
| Discrete tax items | — | — | — | — | — | 0 | — | 0 | 0.00 | ||||||||||||||||||||
| Adjusted | $ | 6,846 | $ | 4,097 | $ | 2,749 | $ | (216) | $ | 2,533 | $ | 2,249 | $ | 1 | $ | 2,248 | $ | 1.51 | |||||||||||
| An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document. | |||||||||||||||||||||||||||||
| Amounts may not add due to rounding. | |||||||||||||||||||||||||||||
BOSTON SCIENTIFIC CORPORATION
Q3 and FY 2026 GUIDANCE RECONCILIATIONS
(Unaudited)
| Net Sales | |||||||||||||||||
| Q3 2026 Estimate | Full Year 2026 Estimate | ||||||||||||||||
| (Low) | (High) | (Low) | (High) | ||||||||||||||
| Reported growth | 3.0 | % | 5.0 | % | 5.5 | % | 6.5 | % | |||||||||
| Impact of foreign currency fluctuations | — | % | — | % | (0.5) | % | (0.5) | % | |||||||||
Operational growth | 3.0 | % | 5.0 | % | 5.0 | % | 6.0 | % | |||||||||
| Impact of certain acquisitions/divestitures | — | % | — | % | — | % | — | % | |||||||||
Organic growth | 3.0 | % | 5.0 | % | 5.0 | % | 6.0 | % | |||||||||
Use of Non-GAAP Financial Measures
To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.
To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits), discrete tax items and other charges (credits) as appropriate. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, “General Methodology and Use of Estimated Annual Effective Tax Rate.” In addition to the explanation below, please refer to Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type, since our most recent Annual Report on Form 10-K, that management excluded as part of these non-GAAP financial measures as well as the reason for excluding each item:
•Restructuring and restructuring-related net charges (credits) - These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring plans take place over a defined timeframe and have a distinct project timeline that requires, and begins subsequent to, approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring plans typically result in duplicative cost and exit costs over the defined timeframe and are not
considered part of our core, ongoing operations. In addition, we may incur certain charges such as severance and other compensation-related charges, fixed asset write-offs, contract cancellations, facility shutdown costs, and inventory write-downs associated with discontinuations of significant product lines. These restructuring plans and activities are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.
•Deferred tax expenses (benefits) - These amounts represent significant non-cash tax benefits arising from internal reorganizations or intra-entity asset transfers. The deferred tax effects related to the establishment and subsequent reversal of net deferred tax assets are excluded from management's assessment of operating performance used for making operating decisions and assessing performance.
•IEEPA tariff refund - This amount relates to the benefit recognized in connection with the recovery of previously incurred tariffs imposed under the International Emergency Economic Powers Act (IEEPA) recognized in Cost of products sold within our unaudited consolidated statements of operations. This amount is excluded from management's assessment of operating performance used for making operating decisions and assessing performance.
The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.
To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.
Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.
Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.
We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by
management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.